ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2022
Prediction of Pancreatic Cancer in Diabetes Patients with Worsening Glycemic Control.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Quantifying Weight Loss Prior to Pancreatic Cancer Diagnosis: A Systematic Review and Meta-Analysis.Cancer medicine · 2026Pooled it
- An Evidence Map of the Women Veterans' Health Literature, 2016 to 2023: A Systematic Review.JAMA network open · 2025Pooled it
- Risk factors and early prediction of pancreatic cancer among patients with diabetes mellitus: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Prediagnostic prescription patterns in pancreatic cancer: a retrospective primary care cohort study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2026Article
- Pancreatic Cancer Screening in Patients with Type 2 Diabetes Mellitus: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Effects of tailored exercise on glycemic and nutritional outcomes in diabetic patients with colorectal cancer and on chemotherapy.World journal of diabetes · 2025Article
- The hidden impact: social isolation and inflammation's role in pancreatic cancer risk among those with diabetes.BMC cancer · 2025Article
- Exposure to Agent Orange and Hepatocellular Carcinoma Among US Military Personnel.JAMA network open · 2023Article
- Pancreatic cancer is associated with medication changes prior to clinical diagnosis.Nature communications · 2023Article
- Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC).Frontiers in genetics · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundWorsening glycemic control indicates elevated risk of pancreatic ductal adenocarcinoma (PDAC). We developed prediction models for PDAC among those with worsening glycemic control after diabetes diagnosis.
methodsIn 2000-2016 records within the Veterans Affairs Health System (VA), we identified three cohorts with progression of diabetes: (i) insulin initiation (
resultsIncidence of PDAC was highest for insulin initiators and greater in males than in females. Optimism-corrected c-indices of the models for predicting 36-month incidence of PDAC in the male population were: (i) 0.72, (ii) 0.70, and (iii) 0.71, respectively. Models performed better for predicting 12-month incident PDAC [c-index (i) 0.78, (ii) 0.73, (iii) 0.76 for males], and worse for predicting 60-month incident PDAC [c-index (i) 0.69, (ii) 0.67, (iii) 0.68 for males]. Model performance was lower among females. For subjects whose model-predicted 36-month PDAC risks were ≥1%, the observed incidences were (i) 1.9%, (ii) 2.2%, and (iii) 1.8%.
conclusionsSex-specific models for PDAC can estimate risk of PDAC at the time of progression of diabetes. IMPACT: Our models can identify diabetes patients who would benefit from PDAC screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.